Cardiff Oncology, Inc.
CRDFNasdaq
$0.88
↑ +0.6%Jul 17 close · end-of-day
Price
1Y↓ -80.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$60.1M
Enterprise Value
$14.1M
P/E
—
P/S
114.6
P/B
1.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$525,000.00
Net Income (TTM)
$1.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-9033.9%
Net Margin
198.7%
ROE
3.0%
ROIC
—
Debt / Equity
—
Net Cash
$46.1M
Return 1Y
-80.2%
Company profile
Cardiff Oncology, Inc. develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer.
- CEO
- Mark Erlander
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- California
- Website
- cardiffoncology.com
Earnings
CRDF Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$41,000.00↓ -62.4%
Diluted EPS-$0.18↓ -10.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $365,993.00 | $359,000.00 | $386,000.00 | $488,000.00 | $683,000.00 | $593,000.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$19.1M | -$28.9M | -$39.9M | -$45.4M | -$48.7M | -$49.0M |
| Net income | -$19.3M | -$28.3M | -$38.7M | -$41,441.00 | -$45,431.00 | -$45,851.00 |
| Diluted EPS | -$1.08 | -$0.73 | -$0.89 | -$0.93 | -$0.95 | -$0.69 |
| Operating cash flow | -$16.3M | -$23.0M | -$33.8M | -$30.9M | -$37.7M | -$37.9M |
| Free cash flow | -$16.5M | -$23.2M | -$34.8M | -$31.5M | -$37.8M | -$38.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -5214.9% | -8037.6% | -10337.3% | -9305.7% | -7123.1% | -8256.3% |
| Net margin | -5275.2% | -7880.5% | -10026.9% | -8.5% | -6.7% | -7.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $163,000.00 | $165,000.00 | $150,000.00 | $109,000.00 | $121,000.00 | $120,000.00 | $243,000.00 | $41,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$12.5M | -$12.6M | -$12.6M | -$14.4M | -$14.8M | -$12.0M | -$7.8M | -$12.8M |
| Net income | -$11.8M | -$11.9M | $33.6M | -$13.4M | -$13.9M | -$11.3M | $38.6M | -$12.3M |
| Diluted EPS | -$0.26 | -$0.25 | -$0.22 | -$0.20 | -$0.21 | -$0.17 | -$0.11 | -$0.18 |
| Operating cash flow | -$9.2M | -$10.5M | -$10.3M | -$12.8M | -$8.3M | -$10.8M | -$6.0M | -$12.3M |
| Free cash flow | -$9.2M | -$10.5M | -$10.3M | — | — | -$10.9M | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -7696.3% | -7637.0% | -8381.3% | -13194.5% | -12212.4% | -9978.3% | -3221.0% | -31341.5% |
| Net margin | -7225.8% | -7184.8% | 22399.0% | -12324.8% | -11523.1% | -9381.7% | 15880.3% | -30109.8% |
Company news
Jul 15, 2026
Jun 2, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-14 | PACE GARY W | Buy | 687,285 | $1.46 | $999,999.68 | filing |
| 2026-07-14 | Mohindru Mani· Chief Executive Officer | Buy | 34,364 | $1.46 | $49,999.62 | filing |
| 2026-06-18 | PACE GARY W | Buy | 30,000 | $1.22 | $36,600.00 | filing |
| 2026-06-18 | Mohindru Mani· Chief Executive Officer | Buy | 24,703 | $1.21 | $29,890.63 | filing |
| 2025-07-30 | PACE GARY W | Buy | 275,000 | $2.45 | $673,750.00 | filing |
| 2025-07-30 | PACE GARY W | Buy | 15,000 | $2.45 | $36,750.00 | filing |
Latest 6 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.